UBS Tips Genomma Stock, Sees M&A
UBS has initiated Mexico’s Genomma with a buy rating and a MXP21.95 target, up from MXP15.40 Monday. Genomma Lab’s priced in June a $200m IPO at MXP16, the low end of a MXP16-20 target, in...
Already have an account?
Subscribe now for unlimited access to all current and archive news, data and market analysis.
Take a free two-week trial now for the latest news, data and market analysis.